Clinical trials: Placebo Drug Interaction
Hutchinson-Gilford Progeria Syndrome, Werner Syndrome
Phase I Study of Progerinin in Healthy Volunteers
PRG-PRO-001 is a Phase I, Randomized, Double-blind, Placebo-Controlled, Single Ascending Dose (SAD) Study including a food interaction study, followed by a Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability…
- Trial name
- NCT04512963
- Testing
- Progerinin
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- PRG Science & Technology Co., Ltd.
Amyotrophic Lateral Sclerosis, Cytochrome P-450 Enzyme System
A Study of LY3873862 in Participants With Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS).
The main purpose of this study in participants with Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS) is to test the safety of different doses and to determine the amount of LY3873862 that gets into the bloodstream and how…
- Trial name
- NCT07883590
- Testing
- LY3873862, CYP450 Drug Cocktail
- Where
- 4 sites in United States, Canada
- Volunteers
- 32 people
- Sponsor
- Eli Lilly and Company
Parkinson's Disease
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics Profile of MT101-5 in Healthy Volunteers
The primary study objective is to establish the safety and tolerability of MT101-5 after a single and multiple dose administrations in healthy volunteers.
- Trial name
- NCT05844787
- Testing
- MT101-5
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Mthera Pharma Co., Ltd.
Healthy
A Study to Assess the Drug-Drug Interaction Between VX-787 and Oseltamivir
The purpose of this study is to investigate the drug-drug interaction between VX-787 and oseltamivir, when co-administered at steady-state in healthy participants.
- Trial name
- NCT02262715
- Testing
- VX-787, Oseltamivir
- Where
- Belgium
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Janssen Infectious Diseases BVBA
Healthy Participants
A Study of PF-07258669 In Healthy Adult Participants
Part A of this study is to evaluate safety, tolerability, and pharmacokinetics (PK) of PF-07258669 after administration of multiple ascending oral doses to healthy adult participants.
- Trial name
- NCT05113940
- Testing
- PF-07258669, Midazolam
- Where
- Belgium
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Pfizer
Nocturia
VA106483 and Alpha Blocker Interaction Study in Elderly Males
The main purpose of this study is to investigate whether the hypotensive effects of an alpha-blocker are increased when VA106483 is given at the same time.
- Trial name
- NCT00879216
- Testing
- VA106483
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Vantia Ltd
Healthy Participants
A Study Investigating the Safety, Tolerability, Drug Levels and Drug Effect of BMS-986278 in Healthy Adult Participants (Part 1) and Japanese Participants (Part 2)
The purpose of this study is to evaluate the safety, tolerability, drug levels and drug effect of BMS-986278 in healthy adult participants and Japanese participants.
- Trial name
- NCT05684289
- Testing
- BMS-986278, Sildenafil
- Where
- 2 sites in United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Healthy Participants
Study of BLU-808 in Healthy Adult Participants
This is a 3-part study. Parts 1 and 2 are randomized, double-blind, placebo-controlled investigations of single ascending doses (SAD) (Part 1) and multiple ascending doses (MAD) (Part 2) of orally administered BLU-808 in healthy…
- Trial name
- NCT06948032
- Testing
- BLU-808, Midazolam
- Where
- United States
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Blueprint Medicines Corporation
Cystic Fibrosis
Drug-Drug Interaction Study of VX-770 and VX-809 in Healthy Subjects
The purpose of this study is to assess the pharmacokinetics and safety of VX-809 and VX-770 alone and in combination in healthy subjects.
- Trial name
- NCT01216046
- Testing
- VX-809, VX-770
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Insomnia
A Study to Assess the Pharmacodynamic Interaction Between Gabapentin and Ethanol in Healthy Subjects
The purpose of this study is to assess the pharmacodynamic interaction between gabapentin and ethanol
- Trial name
- NCT00666796
- Testing
- Ethanol, Gabapentin
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Polycystic Ovary Syndrome
Single Ascending Dose, First-in-Human Study on Safety, Tolerability and Pharmacokinetics of BAY1161116
This study will be conducted in a single center, double-blind with 6 dose escalation groups to evaluate the safety, tolerability, and pharmacokinetics of single ascending doses of BAY1161116.
- Trial name
- NCT03119077
- Testing
- BAY1161116, Itraconazole
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Bayer
Arthritis, Rheumatoid
SB-681323-Methotrexate Interaction Study
SB-681323 is a p38 MAP-kinase inhibitor that has potential uses in inflammatory conditions such as RA. Previous p38 MAP-kinase inhibitors have been hindered in development by liver toxicity.
- Trial name
- NCT00419809
- Testing
- SB-681323 oral tablets
- Where
- 2 sites in Australia
- Volunteers
- 18 people
- Sponsor
- GlaxoSmithKline
Diabetes, Healthy
Effect of Liraglutide on Gastrointestinal Absorption of Several Drugs and Potential Influence of Liraglutide on Intragastric pH
The trial is conducted in Europe. The aim of the trial is to investigate if there is any drug to drug interaction between liraglutide and atorvastatin (Lipitor®), lisinopril (Zestril®), griseofulvin and digoxin (Lanoxin®).
- Trial name
- NCT01518166
- Testing
- liraglutide, atorvastatin, lisinopril
- Where
- Sweden
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Depressive Disorder
28-day Repeat Dose and Drug Interaction Study With Orvepitant (GW823296)
This study is being conducted to obtain information on the safety and tolerability of repeated doses of GW823296 for 28 days in healthy male and female subjects.
- Trial name
- NCT00511654
- Testing
- GW823296 tablet, Midazolam
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
Interaction Study of Clopidogrel 600/150 mg Given Alone or Concomitantly With Omeprazole 80 mg in Healthy Subjects
Primary objective: Assess the effects of clopidogrel (600 mg loading dose followed by 4 days 150 mg/day) on Adenosine diphosphate (ADP)-induced platelet aggregation when given concomitantly with omeprazole 80 mg/day compared to…
- Trial name
- NCT01129414
- Testing
- Clopidogrel, Omeprazole
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Sanofi
Opioid Dependence, Methadone Withdrawal Syndrome
Main Study of Lofexidine and Methadone Pharmacodynamic Interaction in Methadone Maintained Patients
The primary objective of this study is to assess QTc (an interval of the heart rhythm) interaction effects between lofexidine and methadone.
- Trial name
- NCT01650649
- Testing
- Lofexidine HCl, Lofexidine-matching sugar pill
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- USWM, LLC (dba US WorldMeds)
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics
Single-ascending Oral Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-281959 / ACT-246475 in Healthy Male Subjects
Study Part I is a single-ascending dose study. Healthy male subjects to be included in the study and randomized in 6 dose groups, Groups A-F (8 subjects per group).
- Trial name
- NCT01954615
- Testing
- 5 mg ACT-281959 prodrug formulation I (Group A), 20 mg ACT-281959 prodrug formulation I (Group B), ACT-281959 prodrug formulation I (Groups C to G doses to be defined)
- Where
- France
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Erectile Dysfunction
Drug Interaction Study of Avanafil and Enalapril or Amlodipine
The purpose of this study is to determine the change in the blood pressure and pulse rate, pharmacokinetics and the safety when avanafil is taken with either enalapril or amlodipine.
- Trial name
- NCT01117038
- Testing
- avanafil and enalapril, avanafil and amlodipine
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- VIVUS LLC
Alzheimer Disease, Huntington Disease
Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects
This study has been designed to confirm, in healthy subjects, the lack of a clinically important pharmacokinetic interaction between Dimebon, at the proposed maximum commercial dose of 20 mg TID (administered every 8 hours), and…
- Trial name
- NCT00831506
- Testing
- digoxin, dimebon
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Male Volunteer
The Pharmacokinetic Interaction Between CKD-501 and Sulfonylurea
To assess the pharmacokinetic Interaction between CKD-501 and sulfonylurea (Glimepiride) in healthy male subjects.
- Trial name
- CKD-501 DDI (NCT01133431)
- Testing
- CKD-501 0.5 mg tablet, Glimepiride 4 mg tablet
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical